Reversal of Moderate or Superficial Neuromuscular Blockade Induced by Cisatracurium

NCT04920682 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Neostigmine
Neuromuscular Blocking Agents
Muscle Weakness

Interventions

DRUG: Reversal of moderate neuromuscular blockade
DRUG: Reversal of superficial neuromuscular blockade
DRUG: Two-step reversal
DRUG: Placebo

Sponsor

Pontificia Universidade Catolica de Sao Paulo